Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2024

01-03-2024 | Filgrastim | Case report

Antineoplastics

Various toxicities, off-label use and lack of efficacy

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Lee D, et al. Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient. eJHaem 5 : 153-156, No. 1, Feb 2024. Available from: URL: https://dx.doi.org/10.1002/jha2.859
Metadata
Title
Antineoplastics
Various toxicities, off-label use and lack of efficacy
Publication date
01-03-2024
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-54736-x

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue

Case report

Tacrolimus

Case report

Ceftriaxone/Vancomycin

Case report

Interferon-beta-1

Case report

Multiple drugs

Case report

Teclistamab

Case report

Furosemide/Metoprolol-tartrate